Subscribe
kieferpix-istockphoto-com-usa-
Kieferpix / iStockphoto.com
17 July 2018Americas

US court rejects Jazz attempt to revive Xyrem patents

The US Court of Appeals for the Federal Circuit has rejected Jazz Pharmaceuticals’ attempt to revive patents covering its narcolepsy drug Xyrem (sodium oxybate).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Jazz Pharmaceuticals acquires UK medical cannabis firm for $7.2bn
4 February 2021   Jazz Pharmaceuticals has acquired UK medicinal cannabis company GW Pharmaceuticals in a takeover worth $7.2 billion.
Americas
Hikma enters settlement agreement with Jazz to sell Xyrem generic
7 April 2017   Hikma Pharmaceuticals has entered into a settlement agreement with Jazz Pharmaceuticals, following a patent infringement dispute related to Jazz’s drug Xyrem.
Americas
Jazz plays on as Xyrem challenges quashed
15 January 2015   The US Patent and Trademark Office has rejected several petitions that challenged a patent covering Jazz Pharmaceuticals’ narcolepsy drug Xyrem (sodium oxybate).


Editor's picks

‘We created law’: G1/24 and the creation of the ‘diamond standard’
Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025

Editor's picks

Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

More on this story

Big Pharma
Jazz Pharmaceuticals acquires UK medical cannabis firm for $7.2bn
4 February 2021   Jazz Pharmaceuticals has acquired UK medicinal cannabis company GW Pharmaceuticals in a takeover worth $7.2 billion.
Americas
Hikma enters settlement agreement with Jazz to sell Xyrem generic
7 April 2017   Hikma Pharmaceuticals has entered into a settlement agreement with Jazz Pharmaceuticals, following a patent infringement dispute related to Jazz’s drug Xyrem.
Americas
Jazz plays on as Xyrem challenges quashed
15 January 2015   The US Patent and Trademark Office has rejected several petitions that challenged a patent covering Jazz Pharmaceuticals’ narcolepsy drug Xyrem (sodium oxybate).

More on this story

Big Pharma
Jazz Pharmaceuticals acquires UK medical cannabis firm for $7.2bn
4 February 2021   Jazz Pharmaceuticals has acquired UK medicinal cannabis company GW Pharmaceuticals in a takeover worth $7.2 billion.
Americas
Hikma enters settlement agreement with Jazz to sell Xyrem generic
7 April 2017   Hikma Pharmaceuticals has entered into a settlement agreement with Jazz Pharmaceuticals, following a patent infringement dispute related to Jazz’s drug Xyrem.
Americas
Jazz plays on as Xyrem challenges quashed
15 January 2015   The US Patent and Trademark Office has rejected several petitions that challenged a patent covering Jazz Pharmaceuticals’ narcolepsy drug Xyrem (sodium oxybate).

More features

‘We created law’: G1/24 and the creation of the ‘diamond standard’
BMS unit loses cell therapy patent at European Patent Office
Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market
Lord Justice Birss to become chancellor of the High Court
Bankruptcy judge approves $305m sale of genetics testing company
Sanofi successfully challenges rare disease patent in Europe
Bayer appoints new head of IP
WATCH: Policy direction—where are we now?